P21. NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention
© Prinz and Noessner; licensee BioMed Central Ltd. 2014
Published: 12 March 2014
NK cells are appreciated as antitumour effector cells in mouse models and human hematologic malignancies but their relevance in immunosurveillance of human solid tumours remains conflicting due to problems with in situ detection and reports of functional inactivity in the tumour milieu. The study was performed to identify mechanisms that impair NK-cell function in the tumour milieu and thereby identify therapeutic targets that allow recovery of NK-cell functionality.
We used in situ detection and flow cytometry to localise, quantify and profile NK cells of human clear cell renal cell carcinoma (ccRCC) tissue. Strategies were evaluated to reinstate functionality of tumour-derived NK cells. In vitro coculture models were applied to gain mechanistic insight into tumour-induced NK-cell alterations.
Tumour-resident NK cells, compared to NK cells from non-tumour kidney and PBLs, displayed conjoint phenotypic alterations and dysfunction induced by the tumour milieu, which were associated mechanistically with high levels of signaling attenuator diacylglycerol kinase (DGK)-a and blunted mitogen-activated protein kinase pathway activation (ERK1/2, JNK). Reinstating NK-cell functionality was possible by DGK-inhibition or brief IL-2-culture, interventions that de-repressed the ERK pathway. The extent of alteration and magnitude of recovery could be linked to NK-cell frequency within ccRCC-infiltrating lymphocytes, possibly explaining the observed survival benefit of patients with NKhigh tumours.
DGK-mediated dampening of the ERK pathway ensuing in NK-cell dysfunction was identified as an important escape mechanism in ccRCC. DGK and the ERK pathway emerge as promising therapeutic targets to restore suppressed NK-cell activity for the improvement of antitumour immunity.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.